Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.95 |
| ▸ | MEN1 | O00255 | 2/20 | 0.95 |
| ▸ | CASP3 | P42574 | 1/20 | 0.95 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.76 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289672 | 0.99 | FLT3 (0.97) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL5453337 | 0.97 | RAB9A (1.00) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL3916274 | 0.89 | KMT2A (0.97) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL8290663 | 0.88 | FLT3 (1.00) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL919352 | 0.88 | MEN1 (1.00) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL5457818 | 0.87 | FLT3 (1.00) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL8289526 | 0.87 | RAB9A (0.95) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL8289853 | 0.87 | FLT3 (0.97) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL5463079 | 0.87 | FLT3 (1.00) | FLT3RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL8290923 | 0.87 | RAB9A (0.80) | FLT3RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| WO-2020252456-A1 | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-7696244-B2 | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-13 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070265316-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-15 | — | — | US | disclosed |
| WO-2004110352-A2 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | HSPA5, PSMG3, VCP | FLT3 4858/4885RAB9A 858/4885NPC1 809/4885 |
| US-20070265316-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | CFTR, SLC47A1, SLC47A2 | FLT3 3065/4885RAB9A 2319/4885NPC1 438/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885RAB9A 948/4885NPC1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.